Build the Wall: How Pharma Layers NCE and Orphan-Drug Exclusivity to Lock Out Generics
The most important innovation in modern drug markets isn’t always a molecule—it’s a timeline strategy.
In a world where patients want faster access and payers want p…
India’s drug patent “clock” is one of the most misunderstood timelines in global pharma.
On paper, patent protection looks clean: file, publish, grant, enforce. In practice, the duration of exclusivity in India is shaped by a patchwork of statutory rul…
Generic drugs are having a moment—and the real action isn’t in the lab. It’s in the legal clock.
If you think the generic drug market is driven only by science and manufacturing capacity, you’re missing the part that determines when competition can leg…
Biopharma’s “Patent Cliff” Isn’t Just a Legal Event—It’s a Commercial Deadline.
If you’re a biopharma commercial, market access, or vendor partner, you already know the headline: patents expire, exclusivity erodes, and competition arrives faster than m…
Biopharma is entering a new talent cycle—and the “next stop” is hiding in plain sight: biosimilar patent wars.
If you’ve been watching the industry for the last few years, you’ve seen the headlines: blockbuster biologics losing exclusivity, manufacture…
Biosimilar Patent Wars Reveal Exactly Where Biopharma Talent Is Heading Next Read Post »
The internet keeps asking: “Can this drug do that?” The pharmacology keeps sighing.
Every week, another thread goes viral: “Wait—if this medicine treats X, shouldn’t it also help with Y?” It’s a fair question. It’s also where science meets the messy re…
Can This Drug…Do That? The internet keeps asking. The pharmacology keeps sighing. Read Post »
Stop the DIY Drug Patent Search: The FTO Opinion That Could Save You From “Willful” Infringement
In pharma, the most expensive mistake is often the one you didn’t know you were making.
A growing number of companies are treating freedom-to-operate (FTO)…
The quiet shift in pharma contracting: “abuse-deterrent” isn’t just a label claim anymore—it’s a procurement strategy.
Drug patent cliffs don’t just threaten revenue—they reshape how payers, pharmacy benefit managers, and government formularies decide …
Old Drugs, New Signals: What the Side-Effect Conversation Is Really Saying
The side-effect conversation is getting louder—and it’s not just about safety.
For years, “old drugs” were treated like finished products: approved, prescribed, and largely file…
Old Drugs, New Signals: What the Side-Effect Conversation is Really Saying Read Post »
Small molecules vs. biologics: the patent playbook for generics vs. biosimilars is not just different—it’s fundamentally strategic.
If you’re building a drug patent portfolio—or planning for generic or biosimilar entry—you already know the headline: sm…